Jill Biden has received a positive Covid-19 diagnosis on Monday night, according to a statement from the White House. This marks the second time the first lady has tested positive for the virus. Elizabeth Alexander, the first lady’s communications director, reported that she is presently experiencing only mild symptoms and will continue to reside at their home in Rehoboth Beach, Delaware.
Meanwhile, President Joe Biden, who is scheduled to depart for a G20 meeting in India on Thursday, received a negative result for Covid on Monday evening. However, the White House press secretary, Karine Jean-Pierre, announced that the president will undergo regular testing throughout the week and monitor for any symptoms.
The first lady’s positive test result comes after the Bidens’ shared Labor Day weekend. It will be important for President Biden to attend the G20 summit in India. He had intended to meet with Xi Jinping, president of China, but indications indicate that Xi will not be attending the conference. The president is also anticipated to visit Hanoi afterwards in an effort to improve ties with Vietnam. His attendance and his relations with delegates and international leaders may be impacted by any symptoms or positive test findings.
Due to their ages, the president and first lady are both thought to have a higher risk of contracting COVID-19. However, both have had vaccinations, greatly lowering the possibility of developing a serious sickness.
They had previously developed “rebound” cases after contracting the virus approximately a year prior, recovering after taking antiviral medication. The first lady’s recent illness serves as a stark reminder of the virus’s continuous existence and menace. Public health professionals continue to emphasize the value of immunization and attentiveness, and they look forward to the launch of improved vaccinations in the upcoming fall.
Despite the fact that Covid-19 has lost some of its political and public attention, there have been more instances and hospitalizations recently all around the United States, raising worries about the advent of new varieties. Although infection rates and hospitalizations are still lower than they were at the height of the epidemic, alterations in monitoring and decreased testing make it more difficult to precisely track the virus.